Salute e Benessere
BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development
Martin Olin , Chief Executive Officer of BerGenBio stated:
"1L NSCLC STK11m patients are not currently eligible for targeted therapy and face a very poor prognosis. The total market for this patient group is estimated to be between 4 and 5 billion USD . The initiation of Phase 2a of the study of our lead compound bemcentinib in these patients represents an important milestone for the company. Our clinical progress in the quarter combined with the successful capital raise from the warrants exercise positions BerGenBio to advance a new much needed therapeutic option for these patients with high unmet medical need."
The Q1 2024 Financial report is attached to this stock exchange announcement and the report and the Q1 2024 presentation are available at the Company's website https://www.bergenbio.com/investors/financial-reports.
BerGenBio's senior management team will provide a business update today at
10:00 am CET . The presentation will webcast live. To participate in the webcast, please use the following link:
https://channel.royalcast.com/landingpage/hegnarmedia/20240529_1/
A recording of the webcast will be available at www.bergenbio.com in the Investors/Financial Reports section (https://www.bergenbio.com/investors/financial-reports) shortly afterwards.
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Jan Lilleby
jl@lillebyfrisch.no
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, , a potentially first-in-class selective AXL inhibitor in clinical development for STK11 mutated NSCLC and preclinical development for severe respiratory infections.
BerGenBio is based in Bergen, Norway , with a subsidiary in Oxford, UK . The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
https://news.cision.com/bergenbio-asa/r/bergenbio-first-quarter-results-2024--advancing-to-the-next-stage-of-development,c3990167
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/bergenbio-first-quarter-results-2024-advancing-to-the-next-stage-of-development-302157557.html